share_log

Morgan Stanley Maintains Equal-Weight on Alnylam Pharmaceuticals, Raises Price Target to $255

Morgan Stanley Maintains Equal-Weight on Alnylam Pharmaceuticals, Raises Price Target to $255

大摩資源lof維持在阿里拉姆製藥的股票評級爲中性,並將目標價上調至255美元。
Benzinga ·  07/12 13:16

Morgan Stanley analyst Michael Ulz maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Equal-Weight and raises the price target from $250 to $255.

大摩資源lof分析師Michael Ulz保持阿里拉姆製藥(納斯達克:ALNY)的等權重評級,將目標價從$250上調至$255。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論